Zentalis Pharmaceuticals, Inc. Equity Securities, FV-NI, Realized Gain (Loss)
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Equity Securities, FV-NI, Realized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2026-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-12-31 was $376.00K.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for the quarter ending 2025-09-30 was $2.98M, a 47.49% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2025 was $1.24M, a 84.35% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2024 was $7.92M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Realized Gain (Loss) 9 month | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $376.00K derived: sum of 3 quarters · filed 2026-08-06 | $3.35M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $376.00K derived: sum of 2 quarters · filed 2026-05-12 | $3.35M derived: sum of 3 quarters · filed 2026-05-12 | $3.35M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.35M derived: sum of 2 quarters · filed 2026-03-26 | $3.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.24M 10-K · filed 2026-03-26 | ||
| 2025-09-30 | $2.98M 10-Q · filed 2025-11-10 | $2.98M derived: sum of 2 quarters · filed 2026-08-06 | $863.00K 10-Q · filed 2025-11-10 | $2.97M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$2.00K derived: sum of 3 quarters · filed 2026-08-06 | $5.66M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | -$2.00K derived: sum of 2 quarters · filed 2026-05-12 | $5.66M derived: sum of 3 quarters · filed 2026-05-12 | $5.66M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.66M derived: sum of 2 quarters · filed 2026-03-26 | $5.66M derived: sum of 3 quarters · filed 2026-03-26 | $7.92M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $5.67M 10-Q · filed 2025-11-10 | $5.67M derived: sum of 2 quarters · filed 2025-11-10 | $7.92M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $2.25M 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $31.17M 10-Q · filed 2024-05-07 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |